TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Earnings for TG Therapeutics, Inc. (TGTX)
Earnings in 2023 (TTM): $13.06 M
According to TG Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $13.06 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of TG Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $13.06 M | $12.67 M |
| 2022 | $-198,335,000 | $-203,831,000 |
| 2021 | $-348,101,000 | $-355,552,000 |
| 2020 | $-279,381,000 | $-285,878,000 |
| 2019 | $-172,871,000 | $-179,347,000 |
| 2018 | $-173,482,000 | $-173,482,000 |
| 2017 | $-118,476,012 | $-118,476,012 |
| 2016 | $-78,252,894 | $-78,252,894 |
| 2015 | $-62,948,646 | $-62,948,646 |
| 2014 | $-55,781,277 | $-55,781,277 |
| 2013 | $-20,478,210 | $-20,478,210 |
| 2012 | $-25,852,952 | $-18,072,719 |
| 2011 | $-889,071 | $-853,074 |
| 2010 | $1.35 M | $623.65 K |
| 2009 | $-2,831,623 | $-2,793,285 |
| 2008 | $-4,662,702 | $-4,268,858 |
| 2007 | $-12,032,252 | $-12,032,252 |
| 2006 | $-10,001,329 | $-9,695,123 |
| 2005 | $-19,351,153 | $-19,140,997 |
| 2004 | $-6,071,641 | $-5,896,031 |
| 2003 | $-7,220,461 | $-5,960,907 |
| 2002 | $-1,558,147 | $-1,546,935 |
| 2001 | $-1,776,955 | $-1,734,945 |
| 2000 | $-5,895,148 | $-5,802,478 |
| 1999 | $ | $-2,400,000 |
| 1998 | $ | $-2,800,000 |
| 1997 | $-5,100,000 | $-5,200,000 |
| 1996 | $-3,600,000 | $-3,600,000 |